UPDATED Mar 07, 2024
Big ticket companies showing a potential underpricing based on intrinsic value
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
---|---|---|---|---|---|---|---|---|---|---|
AZNAstraZeneca | UK£102.34 | 2.5% | -5.8% | UK£158.6b | UK£127.46 | PE34.1x | E16.7% | 2.2% | ||
GSKGSK | UK£17.11 | 2.8% | 21.2% | UK£69.4b | UK£19.59 | PE14.1x | E9.1% | 3.4% | ||
HIKHikma Pharmaceuticals | UK£18.54 | -5.7% | 3.6% | UK£4.1b | UK£22.66 | PE27.7x | E18.1% | 2.6% | ||
INDVIndivior | UK£17.18 | 0.2% | 14.5% | UK£2.3b | UK£23.88 | PE1499.1x | E43.2% | 0% | ||
HCMHUTCHMED (China) | UK£2.28 | -4.6% | -10.6% | UK£1.9b | UK£4.25 | PE24.7x | E26.1% | n/a |